Antibody Drug Conjugate Linkers for Homogeneous DAR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving homogeneous drug-to-antibody ratios (DARs) and stability, leading to increased clearance rates and variable therapeutic efficacy.
Innovation Solution
Development of linker groups and conjugation methods that allow for site-specific and modular payload installation, including the use of branched linkers and microbial transglutaminase-mediated conjugation, to create ADCs with defined DARs and improved stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional conjugation methods (lysine amide coupling, cysteine maleimide coupling) are used, then the conjugation process is simple and frequently used, but the ADCs exhibit heterogeneous DARs and increased clearance rates
Solution Approach 1:
The patent applies local quality by introducing site-specific conjugation at predetermined locations on the antibody structure (such as engineered cysteine residues or glycan sites) rather than random conjugation. This ensures consistent DARs and homogeneous ADC products while maintaining conjugation simplicity through defined reaction locations.
Solution Approach 2:
The patent employs preliminary action by pre-engineering specific conjugation sites on the antibody structure before the conjugation process. This includes introducing specific amino acid residues or modifying glycan structures in advance, which then enable controlled, homogeneous DAR formation during conjugation without requiring complex process control.
2Ease of manufacture
If traditional conjugation methods are used, then the conjugation process is simple, but the ADCs require strictly controlled production to minimize DAR variation
Solution Approach 1:
By establishing localized conjugation sites with specific chemical properties (such as engineered cysteine residues with defined accessibility), the patent enables simple conjugation chemistry to produce homogeneous ADCs without requiring complex production control systems.
Solution Approach 2:
The patent uses intermediary elements such as engineered amino acid residues or modified glycan structures that serve as predetermined anchors for payload conjugation. These intermediaries simplify the conjugation process while ensuring DAR homogeneity, eliminating the need for strict production control.
3Productivity
If multi-loading strategies are used to increase DAR, then payload loading efficiency increases, but the antibody structure may be destabilized
Solution Approach 1:
The patent applies segmentation by distributing multiple payload conjugation sites across different locations on the antibody structure (such as separate glycan sites or engineered residues on different chains). This allows high DAR while maintaining structural integrity through spatial distribution of conjugation events.
Solution Approach 2:
The patent ensures antibody structure stability by selecting specific local sites for conjugation that do not compromise the overall fold or function of the antibody. Engineered residues and glycan structures are chosen for their ability to accommodate payloads while preserving structural quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in ADCs with enhanced pharmacokinetic profiles, increased therapeutic efficacy, and reduced side effects by ensuring consistent drug delivery and minimizing antibody structure destabilization.
Implementation Method 1
Through MTGase-mediated transpeptidation, this method covalently tethers ADC linkers containing terminal primary amines to the side chain of glutamine 295 (Q295) of the human IgG heavy chain
Data Source
AI summary
In one aspect, the present disclosure provides compounds of the formula:wherein the variables are as defined herein.In another aspect, the present disclosure provides compounds of the formula:wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.